Patents by Inventor Lingli CHEN

Lingli CHEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210126469
    Abstract: Predetermined information indicating an application scene in charging electronic equipment is determined. A target charging mode adapted to the application scene is selected from alternative charging modes based on the predetermined information. Each of the alternative charging modes corresponds to a distinct charging parameter. The electronic equipment is charged based on the target charging mode.
    Type: Application
    Filed: May 12, 2020
    Publication date: April 29, 2021
    Inventors: Changyu SUN, Lingli HAN, Yu CHEN
  • Publication number: 20210041333
    Abstract: A manufacturing method for mass production for a tissue or cell microarray, which is characterized in comprising: using a molding device to mold tissue particles, cultivated cells or collected exfoliated cells (such as exfoliated cells from pleural effusion and ascites), forming the tissue particles from blended fresh tissue, tissue fixed by formalin or another solvent (such as alcohol and so on) or a tissue block embedded in paraffin (blended by a tissue blender), implanting the molded tissue or cells cores in a receptor wax or adhering the molded tissue or cells cores onto a metal plate, and then slicing to obtain a tissue or cell microarray.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 11, 2021
    Inventors: Yingyong HOU, Chen XU, Dongxian JIANG, Qi SONG, Haixing WANG, Yalan LIU, Jie HUANG, Lingli CHEN, Rongkui LUO, Qin HU, Yuan JI, Shaohua LU, Jun HOU, Lijuan LUAN, Jieakesu SU
  • Publication number: 20170087146
    Abstract: An irinotecan hydrochloride composite phospholipid composition, preparation method and uses thereof in the preparation of drugs for treating tumors or drug resistant tumors. The composite phospholipid composition comprises irinotecan hydrochloride, composite phospholipid, cholesterol, long-circulating membrane material, surfactant and a buffer medium. The composition improves stability of lipid formulation and the anti-tumor effect of irinotecan hydrochloride, and can overcome multidrug resistance of a tumor.
    Type: Application
    Filed: March 6, 2015
    Publication date: March 30, 2017
    Inventors: Yaping LI, Lingli CHEN, Zhaolei ZHENG, Zhiwen ZHANG, Wangwen GU